- Home
- GTY vs TNGX Comparison
GTY vs TNGX Comparison
Compare GTY & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GTY | TNGX |
|---|---|---|
| Founded | 1955 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GTY | TNGX |
|---|---|---|
| Price | $33.25 | $16.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $32.20 | $18.75 |
| AVG Volume (30 Days) | 709.1K | ★ 3.4M |
| Earning Date | 05-14-2026 | 06-01-2026 |
| Dividend Yield | ★ 5.85% | N/A |
| EPS Growth | 8.00 | ★ 26.89 |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $221,727,000.00 | $62,384,000.00 |
| Revenue This Year | $8.72 | N/A |
| Revenue Next Year | $7.81 | $13.81 |
| P/E Ratio | $24.58 | ★ N/A |
| Revenue Growth | 9.02 | ★ 48.29 |
| 52 Week Low | $25.39 | $1.04 |
| 52 Week High | $34.02 | $17.63 |
Technical Indicators
Market Signals| Indicator | GTY | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 63.49 | 69.84 |
| Support Level | $26.74 | $5.98 |
| Resistance Level | $34.02 | N/A |
| Average True Range (ATR) | 0.57 | 1.17 |
| MACD | -0.08 | 0.48 |
| Stochastic Oscillator | 80.16 | 89.75 |
Price Performance
Historical ComparisonAbout GTY Getty Realty Corporation
Getty Realty Corp is the real estate investment trust in the U.S. specializing in the acquisition, financing, and development of convenience, automotive, and other single tenant retail real estate. The company's portfolio includes convenience stores, car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, collision), automotive parts retailers, and certain other freestanding retail properties, including drive-thru quick service restaurants. It generates majority of the revenue in the form of rental income.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.